



Public-Private Partnership Involving Chlorion on Short-List for Major Grant

LAVAL, QC, December 2 -- Chlorion Pharma Inc. announced today that the *Consortium québécois sur la découverte du médicament* (CQDM) has selected a public-private partnership involving Chlorion Pharma as one of a few groups invited to submit a full grant proposal in the new year.

Other members of the partnership are McGill University and the Biotechnology Research Institute of the Canadian National Research Council.

The letter of intention adjudicated by the CQDM was entitled "A platform for structural studies of membrane proteins involved in chronic pain", and called for funding of \$2.0M over a three-year period.

Dr. Jeffrey Coull, Acting CEO of Chlorion and an Investigator on the project, articulated the value of the proposed research to his organization: "This interdisciplinary project, to be carried out with some of the top experts in the fields of structural biology and biochemistry, could result in highly detailed topographies for membrane proteins that represent important points of therapeutic intervention. Such details will allow Chlorion to design and optimize small molecules with even higher potency and activity, result, of course, in drugs with improved efficacy and therapeutic index."

The full application to the CQDM is due in February 2010, with the results of the competition announced in June 2010.

About the Company

Chlorion Pharma Inc. is a biopharmaceutical company focused on neurotherapeutics that act via the modulation of chloride in the central nervous system. Presently, the company is developing first-in-class therapeutics for the treatment of neuropathic pain and epilepsy.

For more information, please visit our website at www.chlorion.com.

##